Decreased myocardial β-adrenergic receptor density in relation to increased sympathetic tone in patients with nonischemic cardiomyopathy

Journal of Nuclear Medicine

Volumn 48, Issue 11, 2007, Pages 1777-1782

  Tsukamoto, Takahiro ^a   Morita, Koichi ^a   Naya, Masanao ^a   Inubushi, Masayuki ^a   Katoh, Chietsugu ^a   Nishijima, Kenichi ^b   Kuge, Yuji ^a   Okamoto, Hiroshi ^a   Tsutsui, Hiroyuki ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

adrenergic receptor; Heart failure; Norepinephrine; Sympathetic tone

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 4 (3 TERT BUTYLAMINO 2 HYDROXYPROPOXY) 2 BENZIMIDAZOLONE; BETA ADRENERGIC RECEPTOR; CARBON 11; NEUROHORMONE; NORADRENALIN;

ADULT; AGED; ARTICLE; CARDIOMYOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; IN VIVO STUDY; MALE; MEDIASTINUM; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR DENSITY; SYMPATHETIC TONE;

3-IODOBENZYLGUANIDINE; AGED; CARBON RADIOISOTOPES; CARDIOMYOPATHIES; FEMALE; HEART; HEART FAILURE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MYOCARDIUM; POSITRON-EMISSION TOMOGRAPHY; PRESYNAPTIC TERMINALS; PROPANOLAMINES; RADIOPHARMACEUTICALS; RECEPTORS, ADRENERGIC, BETA; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 36048933736     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.043794     Document Type: Article

References (40)

1. Studies of left ventricular dysfunction (SOLVD): rationale, design and methods - two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol. 1990;66:315-322.
2. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial - the SAVE Investigators. N Engl J Med. 1992;327:669-677.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
4. Schwarz F, Mall G, Zebe H, et al. Determinants of survival in patients with congestive cardiomyopathy: quantitative morphologic findings and left ventricular hemodynamics. Circulation. 1984;70:923-928.
5. Corbett JR, Dehmer GJ, Lewis SE, et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardial infarction. Circulation. 1981;64:535-544.
6. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN. Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure: the V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(suppl):VI17-VI23.
7. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation. 1991;83:778-786.
8. Cohn JN, Levine TB, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819-823.
9. Hall C, Rouleau JL, Moye L, et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation. 1994;89:1934-1942.
10. Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-1969.
11. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509-516.
12. Bristow MR, Hershberger RE, Port JD, et al. Beta-adrenergic pathways in non-failing and failing human ventricular myocardium. Circulation. 1990;82(suppl):I12-I25.
13. Port JD, Bristow MR. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol. 2001;33:887-905.
14. Bristow MR, Ginsburg R, Minobe W, et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
15. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation. 1986;74:1290-1302.
16. Ruffolo RR Jr, Kopia GA. Importance of receptor regulation in the pathophysiology and therapy of congestive heart failure. Am J Med. 1986;80:67-72.
17. 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation. 1993;87:1169-1178.
18. Staehelin M, Simons P, Jaeggi K, Wigger N. CGP-12177: a hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem. 1983;258:3496-3502.
19. 11C]phosgene with iron and iron (III) oxide. Nucl Med Biol. 2002;29:345-350.
20. 11C]CGP-12177, a radioligand for beta-adrenoreceptors. Nucl Med Commun. 2004;25:845-849.
21. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22:22-31.
22. Henderson EB, Kahn JK, Corbett JR, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation. 1988;78:1192-1199.
23. Schofer J, Spielmann R, Schuchert A, Weber K, Schluter M. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252-1258.
24. Delforge J, Syrota A, Lancon JP, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177, and a new graphical method. J Nucl Med. 1991;32:739-748.
25. Delforge J, Mesangeau D, Dolle F, et al. In vivo quantification and parametric images of the cardiac beta-adrenergic receptor density. J Nucl Med. 2002;43:215-226.
26. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr. 1989;2:358-367.
27. Bristow MR, Minobe W, Rasmussen R, et al. Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms. J Clin Invest. 1992;89:803-815.
28. Schafers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res. 1998;82:57-62.
29. Mardon K, Montagne O, Elbaz N, et al. Uptake-1 carrier downregulates in parallel with the beta-adrenergic receptor desensitization in rat hearts chronically exposed to high levels of circulating norepinephrine: implications for cardiac neuroimaging in human cardiomyopathies. J Nucl Med. 2003;44:1459-1466.
30. Sisson JC, Wieland DM, Sherman P, Mangner TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med. 1987;28:1620-1624.
31. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123 metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. J Nucl Med. 1989;30:1182-1191.
32. Merlet P, Dubois-Rande JL, Adnot S, et al. Myocardial beta-adrenergic desensitization and neuronal norepinephrine uptake function in idiopathic dilated cardiomyopathy. J Cardiovasc Pharmacol. 1992;19:10-16.
33. 123I-MIBG in the failing human heart. J Nucl Med. 1999;40:224-231.
34. Cohen-Solal A, Rouzet F, Berdeaux A, et al. Effects of carvedilol on myocardial sympathetic innervation in patients with chronic heart failure. J Nucl Med. 2005;46:1796-1803.
35. Merlet P, Valette H, Dubois-Rande JL, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med. 1992;33:471-477.
36. Merlet P, Benvenuti C, Moyse D, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med. 1999;40:917-923.
37. 123I-MIBG scintigraphy for predicting prognosis in patients with dilated cardiomyopathy. Nucl Med Commun. 1999;20:529-535.
38. Suwa M, Otake Y, Moriguchi A, et al. Iodine-123 metaiodobenzylguanidine myocardial scintigraphy for prediction of response to beta-blocker therapy in patients with dilated cardiomyopathy. Am Heart J. 1997;133:353-358.
39. 123I meta-iodobenzylguanidine imaging in predicting the effectiveness of beta blockers for patients with idiopathic dilated cardiomyopathy before and soon after treatment. Heart. 1999;81:148-152.
40. Spyrou N, Rosen SD, Fath-Ordoubadi F, et al. Myocardial beta-adrenoceptor density one month after acute myocardial infarction predicts left ventricular volumes at six months. J Am Coll Cardiol. 2002;40:1216-1224.